RxSight, Inc.

RXST ·Healthcare, Medical Devices, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-38.9M $-27.5M $-48.6M $-66.8M $-48.7M $27.6M
Depreciation & Amortization $3.3M $3.6M $4.1M $3.9M $4.0M $3.9M
Depreciation
Amortization
Stock-Based Compensation $31.6M $24.6M $15.7M $11.4M $7.6M $4.2M
Net Cash from Operating Activities $-15.5M $-16.9M $-41.6M $-58.9M $-44.7M $-35.2M
Investing Activities
Capital Expenditures $3.8M $5.4M $4.8M $2.4M $1.9M $2.5M
Business Acquisitions
Net Cash from Investing Activities $16.9M $-99.3M $-22.1M $40.0M $-81.9M $15.6M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $1.9M $123.3M $61.5M $6.3M $137.3M $25.2M
Net Change in Cash $3.2M $7.1M $-2.2M $-12.6M $10.7M $5.6M
Free Cash Flow $-19.3M $-22.4M $-46.4M $-61.2M $-46.6M $-37.7M